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Abstract
Brachytherapy, a radiotherapy technique for treating prostate cancer, involves the implantation of
numerous radioactive seeds into the prostate. While the implanted seeds can be easily identified on
a CT image, distinguishing the prostate and surrounding soft tissues is not as straightforward.
Magnetic Resonance Imaging (MRI) offers superior anatomical delineation, but the seeds appear
as dark voids and are difficult to identify, thus creating a conundrum. Cobalt dichloride-N-acetyl-
cysteine (C4) has previously been shown to be promising as an encapsulated contrast agent
marker. We performed spin-lattice relaxation time (T1) and spin-spin relaxation time (T2)
measurements of C4 solutions with varying cobalt dichloride concentrations to determine the
corresponding relaxivities, r1 and r2. These relaxation parameters were investigated at different
field strengths, temperatures and orientations. T1 measurements obtained at 1.5 T and 3.0 T, as
well as at room and body temperature, showed that r1 is field-independent and temperature-
independent. Conversely, the T2 values at 3.0 T were shorter than at 1.5 T, while the T2 values at
body temperature were slightly higher than at room temperature. By examining the relaxivities
with the C4 vials aligned in three different planes, we found no orientation-dependence. With
these relaxation characteristics, we aim to develop pulse sequences that will enhance the C4 signal
against prostatic stroma. Ultimately, the use of C4 as a positive contrast agent marker will
encourage the use of MRI to obtain an accurate representation of the radiation dose delivered to
the prostate and surrounding normal anatomical structures.
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1. Introduction
Low dose rate prostate implant brachytherapy is a radiation therapy technique in which
numerous small radioactive seeds of a given isotope are permanently implanted into the
prostate. As the radioactive isotope decays, the seeds release radiation, damaging the
integrity of the nearby cells (Vacha and Engenhart-Cabillic 2003). To estimate the extent of
the radiation exposure in both the cancerous and normal cells, two main pieces of
information are needed: the radioactive seeds’ precise locations and the boundaries of the
normal structures adjacent to the prostate, such as the bladder and rectum. The current
standard of care is to perform a computed tomography (CT) scan after implantation to
identify the radioactive seeds and verify the radiation dose distribution (Christodouleas et al
2010).
Although the radioactive seeds, which are encapsulated in metal, can be easily visualized on
a CT scan, the prostate anatomy cannot be clearly visualized on a CT scan, especially in the
presence of the metallic artifacts introduced by the seeds. It is well established that magnetic
resonance imaging (MRI) provides superior soft-tissue visualization of the prostate and
normal critical structures. However, the metallic radioactive seeds and spacers appear as
negative voids on MRI images (see Figure 1 for a comparison of MRI and CT images), thus
confounding automatic seed-localization algorithms to reliably detect seed position and
orientation.
Currently available implantable markers have negative contrast on MRI and can be difficult
to differentiate from other structures, such as needle tracks (Bridges 2009). Permanent or
temporary implantable positive MRI contrast agent markers technology for brachytherapy
was recently patented (Frank and Martirosyan 2013) and offers a unique opportunity for
cancer radiation treatment planning, treatment, and subsequent response evaluation in vivo.
The experimental positive contrast marker (C4) has been shown in both in vitro and in vivo
experiments to help localize permanently implantable objects using MRI (Frank et al 2008).
The C4 MRI marker does not alter the treatment or radiation dose distribution and has been
shown to be safe at the dose and volume consistent with a volumetric prostate implant
(Frank et al 2011, Mehlus et al 2013).
MRI contrast agents affect relaxation times (the time that excited protons of water molecules
take to return to their equilibrium state) because the ions in these contrast agents serve as
microscopic but powerful magnets that relax nearby water protons. T1 shortening agents act
as positive contrast agents by shortening the spin-lattice relaxation time (T1) of these water
protons, leading to more rapid magnetization recovery and increased measured signal
intensity. Conversely, T2 shortening agents act as negative contrast agents by shortening the
spin-spin relaxation time (T2), leading to increased dephasing of the transverse signal and
decreased measured signal intensity. The capacity of contrast agents to shorten the
relaxation times of bulk water protons is defined as relaxivity (Lauffer 1996).
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By incorporating the C4 MRI marker into the prostate brachytherapy workflow, MRI may
be used to more accurately assess the dose to the tumor and normal tissue. This can decrease
the time and costs required of patients and hospital staff. In clinics utilizing MRI/CT fusion,
the use of C4 MRI markers alleviates the need for an extra CT scan to localize the seeds,
thereby eliminating additional ionizing radiation to the patient, reducing uncertainties caused
by imprecise registration from MRI/CT fusion and improving the efficiency of the
workflow. In institutions currently only using CT for post-implant dosimetry, better
prevention of recurrence and prediction of side effects can improve the overall quality of life
for patients, thus offsetting the greater upfront financial cost and time to undergo an MRI
exam instead of a CT exam.
Previously MRI characterization of the C4 solution has not been studied. The purpose of this
study was to determine the relaxation characteristics of C4. Using common imaging
sequences, we measured relaxation times, relaxation rates, and relaxivities at two standard
clinical field strengths (1.5 T and 3.0 T), for three conventional scan planes (coronal,
sagittal, and axial), and at two temperatures (room temperature and body temperature).
2. Methods
2.1. Data collection
In the current study, C4 was obtained by dissolving CoCl2·6H2O (cobalt dichloride
hexahydrate) and NAC (N-acetyl-L-cysteine) in water. Keeping the concentration of NAC
in the solution fixed at 2%, we varied the concentration of cobalt dichloride (0.1%, 0.2%,
0.5%, 1.0%, 1.5%, 2.0%, and 5.0%). All stated percentages are weight percentages. To
match the standard unit for relaxivity (mM−1 s−1), the weight percentages were converted
into millimolar (mM), presented in Table 1.
The solutions were separated by cobalt dichloride concentration into 7 cylindrical glass
vials. Two additional vials, one filled only with water and another filled only with 2% NAC,
were used as controls. The 9 vials were placed in a thin transparent plastic cup and arranged
as shown in Figure 2. The plastic cup was then affixed to the center of a cylindrical plastic
container. Water was poured into the space between the plastic cup and the container to
reduce susceptibility artifacts. The container with the 9 samples was then centered in a
receive-only head array for reception with the body coil used for excitation.
We investigated the dependence of relaxation on three parameters: field strength,
orientation, and temperature. For field strength dependence measurements, the samples were
scanned using a 1.5 T and a 3.0 T clinical MRI scanner (Excite HDxt and Discovery MR750
respectively; GE Healthcare, Waukesha, WI). For orientation dependence measurements, the
samples were positioned such that the base of the vials were parallel to the chosen scan
plane—coronal, sagittal, or axial. For temperature dependence measurements, the samples
were placed in a water bath at room temperature (20.3°C as denoted on the console) or body
temperature (37 ± 1°C).
Analysis was performed offline using Matlab 7.9.0. (The MathWorks, Inc., Natick, MA). A
square 7-pixel by 7-pixel region-of-interest (ROI) was defined in the center of each vial on
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the image, away from the vial edges to prevent signal inhomogeneity. The mean and
standard deviation of the signal within the ROI were recorded at each time point.
2.2. Measuring spin-lattice relaxation time (T1)
T1 measurements were obtained using a single-slice inversion recovery spin echo sequence,
which is precise and is the pulse sequence most commonly used for T1 determination. At 1.5
T, we used the following parameters: TI = 50, 100, 200, 400, 800, 1600, 3200 ms; matrix
size = 128 × 128; FOV = 16 cm; TR/TE = 5000 ms/10 ms; bandwidth = ±122.109 kHz;
NEX = 0.5; and slice thickness = 10 mm. At 3.0 T, we used the following parameters: TI =
50, 100, 200, 400, 800, 1600, 3200 ms; matrix size = 256 × 256; FOV = 16 cm; TR/TE =
5000 ms/10 ms; bandwidth = ±62.5 kHz; NEX = 5.0; and slice thickness = 5 mm.
The signal for inversion recovery is typically expressed as
where M0 is the equilibrium magnetization, TI denotes inversion time, and TR denotes
repetition time. For a given concentration, at each TI, the signal was represented by the
mean signal in the ROI and the standard deviation was used to estimate uncertainty. Because
TR and M0 were fixed, we estimated T1 using the Levenberg-Marquardt least-squares
algorithm (Levenberg 1944; Marquardt 1963). For each ROI defined in each vial, we used
the time point with the lowest signal as our initial estimate for T1, which ideally should be
close to the null point. However, T1 was expected to be extremely close to 0 at higher
concentrations (1.5%, 2.0%, and 5% for 1.5 T and 5% for 3.0 T), so to ensure stability for
these points, we used 10 ms for some of the initial estimates for T1.
2.3. Measuring spin-spin relaxation time (T2)
T2 measurements were obtained using a 2D spin-echo sequence. At 1.5 T, we used the
following parameters: TR = 1000 ms; TE = 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200,
250, 300, 350, 400, 500, 600 ms; matrix size = 128 × 128; bandwidth = ±122.109 kHz; FOV
= 16 cm; NEX = 0.5; and slice thickness = 10 mm. At 3.0 T, we used the following
parameters: TR = 5000 ms; TE = 10, 20, 30, 40, 50, 60, 70, 80 ms; matrix size = 256 × 128;
bandwidth = ±62.5 kHz; FOV = 6 cm; NEX = 1; and slice thickness = 10 mm.
Because we used small echo spacing, we fit the measured echo amplitudes to
For each ROI, a first-degree polynomial fitting was performed on the spin echo signals
plotted against time to obtain the initial estimate for T2.
Starting with the initial T1 and T2 estimates, we applied nonlinear regression to the signal
plotted against each inversion/echo time and iteratively applied the least-squares method to
estimate T1 and T2. Relaxivity was defined as the change in relaxation rate of bulk water per
unit concentration of cobalt dichloride. The relaxation rates were calculated and plotted
Lim et al. Page 4






















against cobalt dichloride concentration. Thus, the slopes from the linear fit to this plot result
in relaxivity values r1 and r2.
3. Results
3.1. Effect of field strength
T1 and T2 values measured at 1.5 T and 3.0 T, for cobalt dichloride concentrations ranging
from 0 mM to 211.45 mM, are shown in Figure 3. Corresponding relaxation rates are shown
in Figure 4. The T1 values were similar at both field strengths, even across different cobalt
dichloride concentrations. Hence, the C4 r1 relaxivity values obtained at the two different
field strengths were similar, suggesting that r1 is not dependent on field strength.
However, the T2 values of C4 at 3.0 T were slightly lower than at 1.5 T, translating to
consistently higher spin-spin relaxation rates. Therefore, the value of the slope, which
corresponds directly to the r2 of C4, was higher at 3.0 T than at 1.5 T, suggesting that r2 is
dependent on field strength and that T2 is likely to decrease with increasing field strengths.
Because r1 is not dependent on field strength, the increase in r2 with field strength increases
the relaxivity ratio r2/r1.
3.2. Effect of orientation
The T1 and T2 values measured at coronal, sagittal, and axial orientations are shown in
Figure 5, and Figure 6 shows the relaxation rates across different cobalt dichloride
concentrations. No significant differences in relaxation measurements were observed across
different orientations of the vial with respect to the main magnetic field.
3.3. Effect of temperature
Figure 7 shows the T1 and T2 values measured at room temperature and body temperature,
and Figure 8 shows the corresponding relaxation rates across different cobalt dichloride
concentrations. The T1 values were similar at both room temperature and body temperature
for all cobalt dichloride concentrations investigated. Therefore, the corresponding relaxation
rates were similar for the two temperatures as well, suggesting that r1 is not dependent on
temperature.
Conversely, the T2 of C4 at body temperature was slightly higher than at room temperature,
translating to lower spin-spin relaxation rates. Therefore, the value of the slope, which
corresponds directly to the r2 of C4, was lower at body temperature than at room
temperature. These temperature data sets suggest that r2 is dependent on temperature and
that T2 is likely to increase with increasing temperature. Because r1 is not dependent on
temperature, the decrease in r2 with temperature decreases the relaxivity ratio r2/r1.
In summary, relaxivity measurements at different field strengths, orientations and
temperatures are presented in Table 2.
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The spin-lattice and spin-spin relaxation times and corresponding relaxivities of C4 at
different field strengths, orientations, and temperatures indicate that C4 can be used
effectively as an encapsulated positive contrast agent marker to enable MRI-only post-
implant dosimetric evaluation.
Contrast in MRI mainly occurs because of the differences in signal intensities of various
tissues. Different tissues have unique T1 and T2 values that can be affected by the presence
of positive contrast agents: the greater the concentration of cobalt dichloride ions, the
smaller the T1 and T2 relaxation times. Consistent with our expectations from previous
investigations (Frank et al 2008), the T1-shortening effect of C4 was very dominant;
therefore, a very high signal (positive enhancement) from C4 against the prostatic
background was expected. Because of the innate fast transverse relaxation of prostate tissue,
the T2 shortening effect was not as strong as the T1 shortening effect.
As field strength increases, the corresponding Larmor frequency increases; hence the energy
transfer to the lattice is less efficient. Thus, increased T1 values are expected at high field
strengths, and we did observe this slight increase in T1 at the lower concentrations of cobalt
dichloride. However, the T1 values at the two field strengths agreed well overall. In contrast,
T2 values at 3.0 T decreased at a greater rate with increasing concentration compared with
that at 1.5 T. For cobalt dichloride concentrations <1% (42.49 mM), simply increasing the
concentration to enhance the signal is not feasible because the shorter T2 values at 3.0 T
reduces the effect of T1-shortening. For cobalt dichloride concentrations >1%, increasing the
concentration further offers little gain because the T1-shortening effect plateaus. Thus, the
concentration of 1% cobalt dichloride offered a reasonable compromise of the T1 and T2
changes at the two clinically relevant field strengths to generate a strong signal. In addition,
1% cobalt dichloride in C4 is a low concentration that has been shown to be safe for clinical
use (Frank et al 2013).
Although the spin-spin relaxivity (r2) is higher at 3.0 T than at 1.5 T, the MRI signal
intensity is still dependent on the pulse sequence chosen. The higher r2 values at higher field
strengths simply reaffirm the increased T2-lowering ability, with the same considerations as
stated before.
The main purpose of studying the effects of orientation on the relaxation characteristics of
C4 is to detect any possible MR artifacts. When the C4 marker is placed between the seeds,
the seeds and MR markers could potentially tilt in any direction. Brachytherapy seeds have
been shown to have artifacts that are dependent on the seeds’ orientation with respect to the
main magnetic field (Thomas et al 2009). In the present study, the relaxation times,
relaxation rates, and relaxivities obtained for all three orientations were similar. These
parameters are intrinsic to the cobalt dichloride complex. Therefore, when imaging the
encapsulated C4 marker, the investigation of the origin of any detected artifacts would be
best directed toward scrutinizing extrinsic parameters.
As temperature increases, the correlation time for the interaction decreases, requiring longer
relaxation times and causing relaxation rates to lower, thereby resulting in a decrease in
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relaxivity (Reichenbach et al 1996). In the present study, for cobalt dichloride concentration
of 1%, the change in T1 was not significant, whereas T2 was slightly higher at body
temperature. Pulse sequence parameter adjustments should ideally be done at body
temperature to better simulate clinical conditions, in which the C4 marker will always be at
body temperature. Note that in the present study we evaluated the effects of only two
different temperatures on relaxation: room temperature and the more clinically relevant body
temperature. Any extrapolation of our findings to storage ambient temperature concerns or
nonmedical use clearly warrants further investigation.
Using specific pulse sequences, such as T1-weighted or T2-weighted sequences, can enhance
the differences in signal intensities of various tissues. With knowledge of the relaxation
times of the desired contrast agent concentration, we can optimize pulse sequence
parameters to provide greater contrast between the C4 marker and surrounding tissue.
Previously reported T1 and T2 values for the prostate measured at 3.0 T were 1597 ± 42 ms
and 74 ± 9 ms, respectively (de Bazelaire et al 2004). In the present study, the reported T1
and T2 values for 1% cobalt dichloride at 3.0 T were 138 ± 5 ms and 61 ± 0.2 ms,
respectively. Thus, for example, for a conventional spin echo sequence, we can estimate a
suitable time to apply the 90° pulse such that the separation between C4 and prostate
recovery curves is greatest while the curves for prostate and other tissues remain reasonably
separated.
In addition, we can optimize pulse sequences to provide adequately thin image slices, such
that we may obtain the orientation of the marker. Orientation information from the marker
can be coupled with the seed’s dumbbell artifact to estimate the seed’s orientation. Thus,
treatment planning systems can incorporate seed anisotropy calculations to generate more
accurate dose distributions.
At 1.5 T and 3.0 T, the measured relaxivities in water for Gadolinium-based contrast agents
range from 3 to 5 mM−1 s−1 (Hao et al 2012). The relaxivities we measured for C4 ranged
from 0.1 to 0.4 mM−1 s−1, implying a weaker efficiency in influencing tissue relaxation rates
compared with Gadolinium-based contrast agents. Cobalt has three unpaired electrons,
whereas gadolinium has seven unpaired electrons. Therefore, a higher concentration of
cobalt is needed to achieve the same influence as gadolinium. Note, however, that the C4
solution remains in the polymer casing with no administered tissue uptake, because the main
indication for the C4 MRI marker is an encapsulated contrast agent marker to enable more
accurate localization of brachytherapy seeds. Nevertheless, Frank et al (2011) showed that
the C4 MRI marker is associated with negligible toxicity, enabling the use of very high
concentrations to reach sufficient T1-shortening effects and induce positive contrast.
A caveat of using C4 as an encapsulated marker to be placed next to the seeds is that,
contrary to conventional CT images, the bright signals do not represent the seeds
themselves. Future work will include quantifying the uncertainties associated with
extrapolating seed positions from marker positions and developing a new seed-identification
algorithm to perform the extrapolation.
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Compared to the use of CT, a limitation of using MRI is that geometric distortion may
introduce uncertainty in the reconstructed seed positions. Given the current quality
assurance methods to test MRI geometric distortion, gradient distortion correction
techniques as well as the small size of the prostate, the error of reconstructed seed positions
due to geometric distortion can be managed. However, care must be taken when
investigating dose distributions to critical structures far from the center on images with large
field-of-view. On the other hand, post-implant CT offers prostate geometrical distortion of
another kind – edema, swelling or the inherent indistinct borders can cause the
misrepresentation of anatomy. Although current post-implant CT images provide absolute
coordinates of the seeds, we are also concerned with the relative distance to critical
structures and the distribution of seeds within the prostate volume, thus dose-volume-
histograms are used extensively. The impact of geometric distortion on dose-volume-
histogram parameters of prostate implants can be illuminated in future studies.
Apart from the indications for prostate brachytherapy, C4 can potentially be used as a
contrast agent or as fiducial markers for a variety of other image guided radiation therapy
purposes. Similar to Gadolinium-based contrast agents, the spin-lattice and spin-spin
relaxivities for C4 are approximately the same, suggesting the same T1- or T2-shortening
capability. Hence, the C4 MRI marker could potentially be used as both a positive and a
negative contrast agent. Another potential indication for the C4 MRI marker is to serve as a
fiducial marker for other types of body imaging. The use of both permanent and temporary
implantable fiducial markers is standard in many disease sites. For example, fiducial
markers are placed in the prostate for daily image-guided radiation treatment, in the cervix
for localization and treatment planning, in the breast for tumour localization prior to
lumpectomy, and in the lung for tumour tracking during radiation therapy. There may also
be exciting implications for recurrence prediction and management using multiparametric
MRI. Future studies can look into the potential for correlating the dose distribution within
the prostate on MRI images with additional information obtained using multiparametric
MRI (e.g. apparent diffusion coefficient), to guide the differentiation between radiation
necrosis and recurrent disease.
5. Conclusion
We have reported the spin-lattice and spin-spin relaxation times as a function of
concentration, as well as the corresponding relaxivities. We have also reported the
dependence of these parameters on field strength, orientation, and temperature.
The main indication for C4 is as an encapsulated MRI contrast agent marker for post-
implant dosimetric evaluation. Further testing of the accuracy of the C4 marker (and hence,
seed) localization using images generated from standard clinical pulse sequences is
warranted. Efficacy and feasibility comparisons can also be made against methods that do
not require the use of the C4 MRI marker, such as pulse sequence manipulation like the off-
resonance imaging approach proposed by Whitehead and Ji (2010) that directly exploits the
susceptibility artifacts of the seeds, or image manipulation by modifying the Hounsfield
Units conversion model (Kapanen and Tenhunen 2013) that generates pseudo-CT images.
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Clinical trials for the C4 MRI marker will further illuminate any clinical challenges.
Depending on the pulse sequence used and time lapsed since the brachytherapy procedure,
the C4 MRI marker’s signal may be obscured or confused with other hyperintense sources,
such as adipose tissue, cysts, hemorrhage or edema from infections (Bridges 2009).
The relaxation values obtained indicate that C4 is promising for use as an encapsulated
contrast agent marker to better quantify the radiation dose to cancerous and various
surrounding normal tissue, such that a more accurate picture of acute and late effects of
brachytherapy can be depicted. With a more accurate description of dose distribution is
combined with pre-implant multiparametric-MRI data (Barentsz et al 2012), we could assess
tumour response to the brachytherapy treatment. The C4 MRI marker may thus allow for the
full integration of MRI for post-implant dosimetry, reducing costs, time, and unnecessary
dose of radiation to the patient from CT.
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Comparison of computed tomography (CT; left) and magnetic resonance imaging (MRI;
right) postimplant images. Brachytherapy seeds can be more definitively identified using
CT, but appear as signal voids with MRI. However, the anatomical details of the male pelvis
are clearly more visible with MRI.
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Nine glass vials with increasing concentrations of cobalt dichloride, arranged in a clockwise
fashion. The center vial contained water only and the top vial contained 2% N-acetyl-L-
cysteine (NAC) only; the remaining vials contained 2% NAC and 0.1%, 0.2%, 0.5%, 1.0%,
1.5%, 2.0%, or 5.0% cobalt dichloride.
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Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at 1.5 T and 3.0 T, for
various cobalt dichloride concentrations.
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Spin-lattice relaxation rate, 1/T1, and spin-spin relaxation rate, 1/T2, at 1.5 T and 3.0 T, for
various cobalt dichloride concentrations. The relaxivity (mM−1 s−1) was determined by the
slope from a linear fit of relaxation rate (s−1) plotted against cobalt dichloride concentration
(mM).
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Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at three different vial
orientations, for various cobalt dichloride concentrations.
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Spin-lattice relaxation rate, 1/T1, and spin-spin relaxation rate, 1/T2, at three different vial
orientations, for various cobalt dichloride concentrations. The relaxivity (mM−1 s−1) was
determined by the slope from a linear fit of relaxation rate (s−1) plotted against cobalt
dichloride concentration (mM).
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Spin-lattice relaxation time, T1, and spin-spin relaxation time, T2, at room temperature and
body temperature, for various cobalt dichloride concentrations.
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Spin-lattice relaxation rate, 1/T1, and spin-spin relaxation rate, 1/T2, at room temperature
and body temperature, for various cobalt dichloride concentrations. The relaxivity (mM−1
s−1) was determined by the slope from a linear fit of relaxation rate (s−1) plotted against
cobalt dichloride concentration (mM).
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Table 1
Conversion from weight percentages to millimolar (mM) for various concentrations of cobalt dichloride.
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Table 2
Relaxivities (r1 and r2) for different field strengths, orientations, and temperatures.
r1 (mM−1 s−1) r2 (mM−1 s−1)
Field strength
  1.5 T 0.158 ± 0.003 0.208 ± 0.002
  3 T 0.148 ± 0.002 0.328 ± 0.006
Orientation
  Coronal 0.145 ± 0.001 0.300 ± 0.005
  Sagittal 0.144 ± 0.002 0.315 ± 0.006
  Axial 0.149 ± 0.001 0.324 ± 0.005
Temperature
  20.3°C 0.144 ± 0.002 0.337 ± 0.005
  37°C 0.127 ± 0.002 0.186 ± 0.001
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